Bedaquiline: A Potential New Treatment for Toxoplasmosis by Inhibiting T. gondii Growth and Mitochondrial Function.

https://pubmed.ncbi.nlm.nih.gov/38115043

Bedaquiline, an FDA-approved drug for tuberculosis, shows potential as an alternative treatment for toxoplasmosis by inhibiting T. gondii growth and impairing its mitochondrial function.